Amgen nabs Kyprolis OK in Europe as U.S. competition mounts

It's been more than three years since Amgen's ($AMGN) multiple myeloma treatment Kyprolis won approval from U.S. regulators. Now, it's finally done the same in Europe--and with competition heating up across the pond, the go-ahead couldn't have come at a better time for the California biotech. Earlier this month, it picked up a new competitor in its home market in Johnson & Johnson's ($JNJ) Darzalex. And though that med will come after both Kyprolis and Celgene rival Pomalyst in the disease course, J&J will be armed with data showing that 36% of patients responded to the top dose of Darzalex in a small study, a number that tops Kyprolis' 23%. More from FiercePharmaMarketing

Suggested Articles

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.

While the failure might be a missed chance at revenue, it shouldn’t hurt Ibrance’s ability to rack up sales in the metastatic setting, one exec says.